SUPPORTING ONLINE MATERIAL

Materials and Methods
Vaccine constructs
The plasmid encoding the SIV Gag-Pol-Nef fusion protein and corresponding rAd vector encoding Gag-Pol have been previously described (Ref. 1) . The open reading frames of both vectors were confirmed by DNA sequencing. The vectors encoding Env were modified in the cleavage, furin, and interhelical domain (∆CFI) sites as previously described for HIV Env involving deletion of aa 515-546 and aa 608-625 (Ref. 2) . To generate the SIVmac239 coding sequence, the protein sequence of SIVmac239 (GenBank accession no. M33262) Env was back-translated (GCG package, Genetics Computer Group, Inc., Madison, Wis.) with codons typically utilized in human cells as previously described (Ref. 1) . For the plasmid DNA, gp145∆CFI ,aa 1-714 (numbering based on M33262), was synthesized and for rAd, gp140∆CFI, aa 1-692, were prepared. In the plasmid, a nucleotide deletion mutation at in the position of aa 713 resulted in a 25 aa extension, SCEDPDLLCLLVASHLLFAPPPCLP. In the rAd vector encoding gp140 ∆CFI, a single nucleotide base insertion at position 632 resulted in a frameshift of the COOH-terminal 60 amino acids. Expression of the gene products encoded by the plasmid and rAd vectors was confirmed by Western blot analysis with antisera to SIVmac239.
Experimental groups and vaccination schedule
Six monkeys in each of the following groups were established: 1.) DNASIVmac239 gag/pol/nef prime/rAd-SIVmac239 gag/pol boost; 2.) DNA-SIVmac239 env prime/ rAd-SIVmac239 env boost; 3.) DNA-SIVmac239 gag/pol/nef + DNA-SIVmac239 env prime/rAd-SIVmac239 gag/pol + rAd-SIVmac239 env boost; 4.) rAd-SIVmac239 gag/pol + rAd-SIVmac239 env only; 5.)sham DNA + empty Ad. The animals received the DNA on a schedule of 0, 4 and 8 weeks at a dose of 4 mg/plasmid construct/inoculation and the rAd at week 40 at a dose of 10 11 particles / construct / inoculation.
Challenge virus
A stock of uncloned SIVmac251 was expanded on human PBMC and titered in vivo in rhesus monkeys for use in intravenous challenge studies. All monkeys received 1 ml of a 1:3000 dilution of this stock by intravenous route.
Plasma viral RNA assay
Assays were performed using an ultrasensitive branched DNA amplification assay (Bayer Diagnostics).
Antibodies
The Abs used in this study were: anti-TNF-α-FITC (MAb11; BD Biosciences), anti-CD95-PE (DX2; BD Biosciences), anti-IFN-γ-PE-Cy7 (B27; BD Biosciences), anti-CD28-PerCP-Cy5.5 (L293; BD Biosciences), anti-IL-2-APC (MQ1-17H12; BD Biosciences), anti-CD4-AmCyan (L200; BD Biosciences), anti-CD3-Pacific Blue ® (SP34-2; BD Biosciences), and anti-CD8α-Alexa Fluor ® 700 (RPA-T8; BD Biosciences).
PBMC stimulation and intracellular cytokine staining
PBMC were separated from whole blood by Ficoll density gradient centrifugation. PBMC (10 6 ) were incubated at 37°C in a 5% CO 2 environment for 6 h in the presence of RPMI 1640/10% FCS medium alone (unstimulated), a pool of 15-mer Gag peptides (5 µg/ml each peptide), or staphylococcal enterotoxin B (SEB) (5 µg/ml, Sigma-Aldrich) as a positive control. All cultures contained Monensin (GolgiStop; BD Biosciences) as well as 1 µg/ml anti-CD49d (BD Biosciences). The cultured cells were stained with mAbs specific for cell surface molecules before fixation. The PBMC were washed twice with PBS-2% FCS and then fixed and permeabilized with Cytofix/Cytoperm solution (BD Biosciences) in accordance with the manufacturer's protocol. Cells were washed twice with 1x Perm/Wash buffer (BD Biosciences) and then stained with anti-cytokine mAb. Anti-cytokine mAb titers for optimal staining were determined in preliminary experiments. Cells were washed twice with 1x Perm/Wash buffer and then fixed in 1.5% formaldehyde-PBS. Samples were collected on a LSR II instrument (BD Biosciences) and analyzed using FlowJo software (Tree Star). Approximately 100,000 to 300,000 events in the lymphocyte gate were acquired. The background level of cytokine staining varied from sample to sample, but was typically <0.01% of the CD4 + T lymphocytes and below 0.05% of the CD8+ T lymphocytes. The only samples considered positive were those in which the percentage of cytokine-staining cells were at least twice that of the background or in which there was a distinct population of cytokine brightly positive cells.
Virus Neutralization Assay.
Neutralization was measured as a function of Tat-induced luciferase reporter gene expression after a single round of infection in TZM-bl cells as described (Ref. 3) . TZMbl cells were obtained from the NIH AIDS Research and Reference Reagent Program, as contributed by John Kappes and Xiaoyun Wu. Neutralization titers are the serum dilution at which relative luminescence units (RLU) were reduced 50% compared to virus control wells after subtraction of background RLUs. The assay stock of primary SIVmac251 was prepared in human PBMC and titrated in TZM-bl cells.
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Statistical analysis of survival curve differences
We have carried out statistical testing of the difference of the survival curves between the group of six unvaccinated monkeys and the group of 24 vaccinated monkeys using the method of D. P. Harrington and T. R. Fleming (Biometrika 69:553-566,1982) as programmed in the "survdiff" function of the Splus statistical software package. In this method the difference of curves is quantified as a chisquare for the net difference in survival rates, interval by interval, over all the intervals encoded in the data. Because no small-sample modification of significance levels is afforded in the Splus package, we computed the actual permutation distribution of the chisquare when the true vaccination status was replaced, over and over, by a random selection of 6 of the 30 cases to serve as the "unvaccinated". On 5000 permutations, the empirical significance level of the observed chisquare was p~0.008 on a logrank assumption (proportional hazards between the groups) and 0.004 on the assumption of shifts in a logistic function. We take the larger p-value as a plausible conservative estimate of the significance of the difference of curves conveyed in Figure 3A . Thus, the survival difference between the vaccinated and control monkeys is statistically significant. 
